24TH MEETING OF THE WHO EXPERT COMMITTEE ON THE SELECTION AND USE OF ESSENTIAL MEDICINE

Updated from the Global Accelerator for Paediatric formulations (GAP-f)

24 April 2023

Martina Penazzato MD, MSc, PhD
GAP-f lead
Research for Health-Science Division
WHO
What is the Global Accelerator for Paediatric formulations?

Our Vision
All children have equitable access to the medicines they need.

What Makes Us Unique
We work across the entire life cycle of paediatric drug development.

Our Mission
Remove barriers to developing and delivering appropriate, quality, affordable and accessible medicines for children and contribute to universal health coverage by spurring collaboration across stakeholders to identify gaps, set priorities for needs and accelerate product investigation, development and delivery to improve and save the lives of children.

Our Network
GAP-f is a WHO network, created to respond to the paediatric treatment gap.
A concerted response across the product life-cycle

**Prioritizing and Evaluating:**
Developing a prioritized drug portfolio of the most needed formulations and assisting in the design and implementation of efficient, and high-quality clinical trials.

**Developing:**
Establishing and maintaining relationships to launch effective products and supporting regulatory submission activities to facilitate paediatric medicine approvals.

**Delivering:**
Supporting efforts to introduce new, adapted formulations in an equitable, accelerated, safe and coordinated manner.

Accelerating priority paediatric drug formulation development and uptake
GAP-f’s three-tiered approach provides the framework to deliver impact

Prioritize and Align
- Set global priorities for therapeutic areas and missing formulations
- Communicate global gaps and priorities through targeted advocacy
- Align stakeholders’ priorities and action to respond to global needs
- Monitor and track global research and development pipelines, gaps, stakeholders and investments

Accelerate
- Facilitate collaborative efforts and mobilize partners to minimize barriers that inhibit innovation and access to paediatric formulations and stimulate activities for acceleration
- Identify and promote best practices to accelerate clinical research, product development and delivery activities
- Support innovations to advance the development of original research methodologies, novel technologies, and innovative financing

Intervene
- Address gaps by facilitating, leading or fundraising for product specific projects on clinical research, development, regulatory, access and delivery
- Support GAP-f partners and engage public and private stakeholders to minimize or eliminate product-specific bottlenecks
The central role of EML in getting better medicines to children

**EML PROJECT AND EML BIANNUAL REVISION**

**PADO PROCESSES AND EOI PERIODIC REVISION**

**ESSENTIAL MEDICINES LIST ADOPTION THE CRITICAL TOOL TO ENSURE MORE OPTIMAL MEDICINES ARE USED IN COUNTRIES**
This expert committee will be asked to consider several changes to ensure age-appropriateness of essential medicines.

The basis for the changes proposed come from a 2 years process that GAPf partners contributed to and included thorough assessment of needs, gaps and access.

Comprehensive analysis of the appropriateness of formulations of medicines currently included on the WHO EMLc:
- Identify formulations for potential addition/removal
- Identify formulation gaps where child-friendly formulations are lacking
Acknowledging the efforts of the EML committee in prioritizing medicines for children, including formulations.

Evidence of clinical benefit of WHO essential anticancer medicines for children, 2011–2021

Lin Bai, Yue Zhan, Yue Zhou, Yichen Zhang, Luwen Shi, Sumit Gupta, Avram Denburg, and Xiaodong Guan

*Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, Beijing, 100019, China
1Department of Pharmacy, Peking University People’s Hospital, Beijing, 100044, China
2International Research Center for Medicinal Administration, Peking University, Beijing, 100019, China
3Division of Haematology/Oncology, Hospital for Sick Children, Toronto, ON, M5G 1X8, Canada
4Department of Paediatrics, Faculty of Medicine, University of Toronto, Toronto, ON, M5G 1X8, Canada

Accessibility of Medicines for Children: A Systematic Review

Zhe Chen, Siyu Li, Linan Zeng, Yan Liu, Miao Zhang, Imti Choonara, and Lingli Zhang

1Department of Pharmacy, West China Second University Hospital, Sichuan University, Chengdu, China
2Evidence-based Pharmacy Center, West China Second University Hospital, Sichuan University, Chengdu, China
3Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Chengdu, China
4West China School of Pharmacy, Sichuan University, Chengdu, China
5West China School of Medicine, Sichuan University, Chengdu, China
6Academic Division of Child Health, Derbyshire Children’s Hospital, University of Nottingham, Derby, United Kingdom

Fostering initiatives to ensure that these efforts are translated into policy and practice at country level.
GAP-f is only as strong as its partners

WHO sincerely thanks all contributors to GAP-f’s work for their dedication, insights, trust and engagement
Thank you